SANA vs. ARQT, TARS, HRMY, TVTX, JANX, AGIO, IRON, APGE, MESO, and VERA
Should you be buying Sana Biotechnology stock or one of its competitors? The main competitors of Sana Biotechnology include Arcutis Biotherapeutics (ARQT), Tarsus Pharmaceuticals (TARS), Harmony Biosciences (HRMY), Travere Therapeutics (TVTX), Janux Therapeutics (JANX), Agios Pharmaceuticals (AGIO), Disc Medicine (IRON), Apogee Therapeutics (APGE), Mesoblast (MESO), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry.
Sana Biotechnology vs.
Sana Biotechnology (NASDAQ:SANA) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.
Arcutis Biotherapeutics received 45 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 66.67% of users gave Arcutis Biotherapeutics an outperform vote while only 63.89% of users gave Sana Biotechnology an outperform vote.
Sana Biotechnology currently has a consensus price target of $10.80, suggesting a potential upside of 531.58%. Arcutis Biotherapeutics has a consensus price target of $18.80, suggesting a potential upside of 19.52%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, equities analysts clearly believe Sana Biotechnology is more favorable than Arcutis Biotherapeutics.
Sana Biotechnology has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -140.97%. Sana Biotechnology's return on equity of -84.22% beat Arcutis Biotherapeutics' return on equity.
88.2% of Sana Biotechnology shares are owned by institutional investors. 31.1% of Sana Biotechnology shares are owned by company insiders. Comparatively, 9.5% of Arcutis Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Arcutis Biotherapeutics has higher revenue and earnings than Sana Biotechnology. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.
Sana Biotechnology has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500.
In the previous week, Sana Biotechnology had 16 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 24 mentions for Sana Biotechnology and 8 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.02 beat Sana Biotechnology's score of 0.09 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.
Summary
Sana Biotechnology beats Arcutis Biotherapeutics on 11 of the 16 factors compared between the two stocks.
Get Sana Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for SANA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sana Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:SANA) was last updated on 3/29/2025 by MarketBeat.com Staff
